MRNA - Moderna, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
MRNA price evolution
MRNA
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2907 | $2932 | $3801 | $3441 |
| Short term investments | $5697 | $4641 | $4658 | $5482 |
| Net receivables | $892 | $1866 | $232 | $1113 |
| Inventory | $202 | $487 | $715 | $732 |
| Total current assets | $10325 | $10799 | $10599 | $12122 |
| Long term investments | $4677 | $5273 | $6105 | $7442 |
| Property, plant & equipment | $2658 | $2717 | $2410 | $2135 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $8101 | $8651 | $11285 | $12003 |
| Total investments | $10374 | $9914 | $10763 | $12924 |
| Total assets | $18426 | $19450 | $21884 | $24125 |
| Current liabilities | ||||
| Accounts payable | $520 | $494 | $310 | $389 |
| Deferred revenue | $651 | $1538 | $1732 | $1892 |
| Short long term debt | ||||
| Total current liabilities | $3015 | $4385 | $3123 | $3499 |
| Long term debt | $1218 | $1272 | $947 | $927 |
| Total noncurrent liabilities | $1557 | $1610 | $1812 | $1763 |
| Total debt | $1218 | $1272 | $947 | $927 |
| Total liabilities | $4572 | $5995 | $4935 | $5262 |
| Shareholders' equity | ||||
| Retained earnings | $13606 | $13389 | $17019 | $18399 |
| Other shareholder equity | -$123 | -$211 | -$263 | -$267 |
| Total shareholder equity | $13854 | $13455 | $16949 | $18863 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2907 | $3205 | $6848 | $2624.88 |
| Short term investments | $5697 | $6697 | $3879 | $1983.76 |
| Net receivables | $892 | $1385 | $3175 | $1390.56 |
| Inventory | $202 | $949 | $1441 | $46.53 |
| Total current assets | $10325 | $13431 | $16071 | $6297.88 |
| Long term investments | $4677 | $8318 | $6855 | $649.9 |
| Property, plant & equipment | $2658 | $2139 | $1383 | $387.09 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $8101 | $12427 | $8598 | $1038.87 |
| Total investments | $10374 | $15015 | $10734 | $2633.66 |
| Total assets | $18426 | $25858 | $24669 | $7336.75 |
| Current liabilities | ||||
| Accounts payable | $520 | $487 | $302 | $18.36 |
| Deferred revenue | $651 | $2711 | $6868 | $4044.61 |
| Short long term debt | ||||
| Total current liabilities | $3015 | $4923 | $9128 | $4388.81 |
| Long term debt | $1218 | $912 | $705 | $207.29 |
| Total noncurrent liabilities | $1557 | $1812 | $1396 | $386.57 |
| Total debt | $1218 | $1004 | $705 | $207.29 |
| Total liabilities | $4572 | $6735 | $10524 | $4775.38 |
| Shareholders' equity | ||||
| Retained earnings | $13606 | $18320 | $9958 | -$2243.52 |
| Other shareholder equity | -$123 | -$370.04 | -$24 | $3 |
| Total shareholder equity | $13854 | $19123 | $14145 | $2561.38 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2811 | $1831 | $344 | $1862 |
| Cost of revenue | $929 | $2241 | $731 | $792 |
| Gross Profit | $1882 | -$410 | -$387 | $1070 |
| Operating activities | ||||
| Research & development | $1406 | $1160 | $1148 | $1131 |
| Selling, general & administrative | $470 | $442 | $332 | $305 |
| Total operating expenses | $1876 | $1602 | $1480 | $1436 |
| Operating income | $6 | -$2012 | -$1867 | -$366 |
| Income from continuing operations | ||||
| EBIT | $70 | -$1958 | -$1749 | -$305 |
| Income tax expense | -$147 | $1672 | -$369 | -$384 |
| Interest expense | ||||
| Net income | ||||
| Net income | $217 | -$3630 | -$1380 | $79 |
| Income (for common shares) | $217 | -$3630 | -$1380 | $79 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6848 | $19263 | $18471 | $803.39 |
| Cost of revenue | $4693 | $5416 | $2617 | $7.93 |
| Gross Profit | $2155 | $13847 | $15854 | $795.46 |
| Operating activities | ||||
| Research & development | $4845 | $3295 | $1991 | $1370.34 |
| Selling, general & administrative | $1549 | $1132 | $567 | $188.27 |
| Total operating expenses | $6394 | $4427 | $2558 | $1558.61 |
| Operating income | -$4239 | $9420 | $13296 | -$763.14 |
| Income from continuing operations | ||||
| EBIT | -$3942 | $9575 | $13285 | -$744.51 |
| Income tax expense | $772 | $1213 | $1083 | $2.55 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$4714 | $8362 | $12202 | -$747.06 |
| Income (for common shares) | -$4714 | $8362 | $12202 | -$747.06 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $217 | -$3630 | -$1380 | $79 |
| Operating activities | ||||
| Depreciation | $202 | $249 | $92 | $78 |
| Business acquisitions & disposals | -$85 | |||
| Stock-based compensation | $79 | $77 | $74 | $75 |
| Total cash flows from operations | $622 | -$1600 | -$915 | -$1225 |
| Investing activities | ||||
| Capital expenditures | -$220 | -$140 | -$234 | -$113 |
| Investments | -$318 | $929 | $2178 | $2209 |
| Total cash flows from investing | -$538 | $789 | $1944 | $2011 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15 | $7 | -$612 | -$517 |
| Net borrowings | -$124 | -$65 | -$56 | -$25 |
| Total cash flows from financing | -$109 | -$58 | -$668 | -$542 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$25 | -$869 | $361 | $244 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$4714 | $8362 | $12202 | -$747.06 |
| Operating activities | ||||
| Depreciation | $621 | $348 | $232 | $93.54 |
| Business acquisitions & disposals | -$85 | |||
| Stock-based compensation | $305 | $226 | $142 | $93.02 |
| Total cash flows from operations | -$3118 | $4981 | $13620 | $2026.97 |
| Investing activities | ||||
| Capital expenditures | -$707 | -$400 | -$284 | -$67.45 |
| Investments | $4998 | -$4776 | -$8239 | -$1604.48 |
| Total cash flows from investing | $4206 | -$5176 | -$8523 | -$1671.93 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$1107 | -$3264 | -$733 | $2039.41 |
| Net borrowings | -$270 | -$184 | -$140 | -$6.21 |
| Total cash flows from financing | -$1377 | -$3448 | -$873 | $2033.19 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$289 | -$3643 | $4224 | $2388.24 |
News
Fundamentals
| Market cap | $41.14B |
|---|---|
| Enterprise value | $39.45B |
| Shares outstanding | 381.28M |
| Revenue | $6.85B |
|---|---|
| EBITDA | -$3.32B |
| EBIT | -$3.94B |
| Net Income | -$4.71B |
| Revenue Q/Q | -44.71% |
| Revenue Y/Y | -64.45% |
| P/E ratio | -8.73 |
|---|---|
| EV/Sales | 5.76 |
| EV/EBITDA | -11.88 |
| EV/EBIT | -10.01 |
| P/S ratio | 6.01 |
| P/B ratio | 2.94 |
| Book/Share | 36.66 |
| Cash/Share | 7.62 |
| EPS | -$12.36 |
|---|---|
| ROA | -22.48% |
| ROE | -29.87% |
| Debt/Equity | 0.33 |
|---|---|
| Net debt/EBITDA | -0.50 |
| Current ratio | 3.42 |
| Quick ratio | 3.36 |